Associated Papers
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Tsukahara S et al.
Cancer Medicine, 2025
Comparison of androgen receptor mutation detection between plasma extracellular vesicle DNA and cell-free DNA and its relationship to prostate cancer prognosis.
Ding T et al.
Annals of Medicine, 2024
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer.
Yang B et al.
Iscience, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ.
Ravindran F et al.
Journal of Cancer Research and Clinical Oncology, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.
Alegre-Martí A et al.
Science Advances, 2023
Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z et al.
Prostate Cancer and Prostatic Diseases, 2023
Simulating androgen receptor selection in designer yeast.
Zhang H et al.
Synthetic and Systems Biotechnology, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.
Radaeva M et al.
Cells, 2022
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Towards precision oncology in advanced prostate cancer.
Ku SY et al.
Nature Reviews. Urology, 2019
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel J et al.
Oncotarget, 2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S et al.
Cancer Research, 2017
Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E et al.
Endocrine Connections, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
Dalal K et al.
Molecular Cancer Therapeutics, 2017
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT et al.
Oncotarget, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW et al.
Jama Oncology, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016
Plasma AR and abiraterone-resistant prostate cancer.
Romanel A et al.
Science Translational Medicine, 2015
Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.
O'Mahony OA et al.
Molecular Cancer Research : Mcr, 2008